HU197988B - Process for producing lyophilized pharmaceutical product containing anthracycline - glycoside - derivative - Google Patents

Process for producing lyophilized pharmaceutical product containing anthracycline - glycoside - derivative Download PDF

Info

Publication number
HU197988B
HU197988B HU853988A HU398885A HU197988B HU 197988 B HU197988 B HU 197988B HU 853988 A HU853988 A HU 853988A HU 398885 A HU398885 A HU 398885A HU 197988 B HU197988 B HU 197988B
Authority
HU
Hungary
Prior art keywords
doxorubicin
hcl
methyl
hydroxybenzoic acid
acid
Prior art date
Application number
HU853988A
Other languages
English (en)
Hungarian (hu)
Other versions
HUT40759A (en
Inventor
Gaetano Gatti
Diego Oldani
Carlo Confalonieri
Luciano Gambini
Original Assignee
Erba Carlo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erba Carlo Spa filed Critical Erba Carlo Spa
Publication of HUT40759A publication Critical patent/HUT40759A/hu
Publication of HU197988B publication Critical patent/HU197988B/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU853988A 1984-10-22 1985-10-15 Process for producing lyophilized pharmaceutical product containing anthracycline - glycoside - derivative HU197988B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848426672A GB8426672D0 (en) 1984-10-22 1984-10-22 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
HUT40759A HUT40759A (en) 1987-02-27
HU197988B true HU197988B (en) 1989-07-28

Family

ID=10568553

Family Applications (1)

Application Number Title Priority Date Filing Date
HU853988A HU197988B (en) 1984-10-22 1985-10-15 Process for producing lyophilized pharmaceutical product containing anthracycline - glycoside - derivative

Country Status (35)

Country Link
US (4) US4675311A (enEXAMPLES)
JP (1) JPH0611700B2 (enEXAMPLES)
KR (1) KR920005813B1 (enEXAMPLES)
CN (1) CN85107562B (enEXAMPLES)
AT (1) AT401345B (enEXAMPLES)
AU (1) AU572003B2 (enEXAMPLES)
BE (1) BE903484A (enEXAMPLES)
BG (1) BG60934B2 (enEXAMPLES)
CA (1) CA1248453A (enEXAMPLES)
CH (1) CH667594A5 (enEXAMPLES)
CS (1) CS270421B2 (enEXAMPLES)
DE (1) DE3536896C2 (enEXAMPLES)
DK (1) DK165620C (enEXAMPLES)
ES (1) ES8605374A1 (enEXAMPLES)
FI (2) FI853913A7 (enEXAMPLES)
FR (1) FR2571966B1 (enEXAMPLES)
GB (2) GB8426672D0 (enEXAMPLES)
GR (1) GR852549B (enEXAMPLES)
HK (1) HK94390A (enEXAMPLES)
HU (1) HU197988B (enEXAMPLES)
IE (1) IE56992B1 (enEXAMPLES)
IL (1) IL76732A (enEXAMPLES)
IT (1) IT1186779B (enEXAMPLES)
MY (1) MY103956A (enEXAMPLES)
NL (1) NL191308C (enEXAMPLES)
NO (1) NO170616C (enEXAMPLES)
NZ (1) NZ213885A (enEXAMPLES)
PH (1) PH23982A (enEXAMPLES)
PT (1) PT81347B (enEXAMPLES)
RU (2) RU1836088C (enEXAMPLES)
SE (1) SE467520B (enEXAMPLES)
SG (1) SG80290G (enEXAMPLES)
UA (2) UA19169A (enEXAMPLES)
YU (1) YU46160B (enEXAMPLES)
ZA (1) ZA858033B (enEXAMPLES)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124318A (en) * 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.R.L. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5124317A (en) * 1985-08-02 1992-06-23 Farmitalia Carlo Erba S.P.A. Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
US5977082A (en) * 1985-08-02 1999-11-02 Pharmacia & Upjohn Company Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
DE3741037A1 (de) * 1986-12-05 1988-06-09 Erba Farmitalia Injizierbare, gebrauchsfertige loesungen, welche ein antitumor-anthracyclinglycosid enthalten
JP2603480B2 (ja) * 1987-08-05 1997-04-23 住友製薬株式会社 安定化されたアンスラサイクリン系製剤
DE3801178A1 (de) * 1988-01-18 1989-07-27 Hoechst Ag Stabilisierte trockenzubereitung zytostatisch wirksamer anthracyclin-antibiotika und verfahren zu ihrer herstellung
US6300362B1 (en) 1990-07-25 2001-10-09 Novartis Ag (Formerly Sandoz Ltd.) Stabilized pharmaceutical compositions comprising acid donors
DE69737510T2 (de) 1996-12-30 2007-12-06 Battelle Memorial Institute, Columbus Verwendung eines unverkapselten Antikrebs-Arzneimittels zur Herstellung einer Zubereitung zur Behandlung von Neoplasmen durch Inhalation
US5942508A (en) * 1997-02-04 1999-08-24 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
RU2292216C2 (ru) * 2000-10-31 2007-01-27 Фарма Мар, С.А. Кахалалид f
KR100970528B1 (ko) 2002-02-22 2010-07-16 쉐링 코포레이션 항신생물제, 특히 테모졸로마이드의 약제학적 제형, 이의제조 및 사용 방법
DK1474995T3 (da) * 2003-05-06 2013-02-18 Gumlink As Fremgangsmåde til fremstilling af tyggegummigranulater, et gummisammensætningsekstruder- og granuleringssystem og et tyggegummiprodukt
US20090099346A1 (en) * 2003-07-02 2009-04-16 Victor Matvienko Thermally stable crystalline epirubicin hydrochloride
CN100412084C (zh) * 2003-07-02 2008-08-20 獀洛克斯股份有限公司 热稳定的结晶盐酸表柔比星及其制造方法
SI2263694T1 (sl) * 2003-09-25 2013-09-30 Astellas Pharma Inc. Antitumorsko sredstvo, ki obsega inhibitor histon-deacetilaze FK228 in inhibitor topoizomeraze II doksorubicin
RU2262923C2 (ru) * 2003-12-25 2005-10-27 Государственное образовательное учреждение высшего профессионального образования Курский государственный медицинский университет Министерства здравоохранения Российской Федерации Иммобилизованная форма доксорубицина
US7388083B2 (en) * 2005-03-07 2008-06-17 Solux Corporation Epimerization of 4′-C bond and modification of 14-CH3-(CO)-fragment in anthracyclin antibiotics
JP2008513519A (ja) * 2005-05-11 2008-05-01 シコール インコーポレイティド 安定した凍結乾燥されたアントラサイクリングリコシド
EP1921919B1 (en) 2005-07-14 2012-04-04 Lithera, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
CN101331147B (zh) * 2005-12-13 2011-11-30 苏洛克股份有限公司 用于制备4-脱甲基柔红霉素的方法
US8802830B2 (en) * 2005-12-20 2014-08-12 Solux Corporation Synthesis of epirubicin from 13-dihydrodaunorubicine
US8148338B2 (en) * 2006-02-22 2012-04-03 Supratek Pharma Inc. Doxorubicin formulations for anti-cancer use
US7470672B2 (en) * 2006-07-31 2008-12-30 Savvipharm Inc. Compositions and methods of reducing tissue levels of drugs when given as orotate derivatives
EP2152312B1 (en) * 2007-05-16 2014-12-31 KTB Tumorforschungsgesellschaft mbH Low-viscous anthracycline formulation
US8227430B2 (en) 2007-09-04 2012-07-24 Meiji Seika Pharma Co., Ltd Injectable, injection solution, and injection kit preparation
US20100234314A1 (en) * 2007-10-26 2010-09-16 Pfizer Inc. Idarubicin for the treatment of lymphoma in a dog
US8357785B2 (en) * 2008-01-08 2013-01-22 Solux Corporation Method of aralkylation of 4′-hydroxyl group of anthracylins
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
CN102869363A (zh) * 2010-01-15 2013-01-09 利赛拉公司 冻干的块状制剂
UA111822C2 (uk) 2010-11-24 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Новамедіка" Монотерапевтичий препарат селективного ліпофільного бета-агоніста тривалої дії і спосіб косметичного лікування ожиріння і контурного випинання
DE102011103751A1 (de) 2011-05-31 2012-12-06 Heraeus Precious Metals Gmbh & Co. Kg Kristallisierung von Epirubicinhydrochlorid
DE102011111991A1 (de) * 2011-08-30 2013-02-28 Lead Discovery Center Gmbh Neue Cyclosporin-Derivate
DK2931042T3 (da) 2012-12-13 2021-06-07 Cytrx Corp Anthracyclinformuleringer
CA2912908C (en) 2013-06-05 2021-06-08 Cytrx Corporation Cytotoxic agents comprising covalently protein binding groups for treating brain cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) * 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4039663A (en) * 1975-03-19 1977-08-02 Societa' Farmaceutici Italia S.P.A. Daunomycins, process for their uses and intermediates
GB1506200A (en) * 1975-04-30 1978-04-05 Farmaceutici Italia Glycosides
GB1567456A (en) * 1976-11-16 1980-05-14 Farmaceutici Italia Daunomycin derivatives
US4177264A (en) * 1977-10-17 1979-12-04 Sri International N-benzyl anthracyclines
GB2007645B (en) * 1977-10-17 1982-05-12 Stanford Res Inst Int Benzyl anthracyclines and pharmaceutical compositions containing them
JPS563851A (en) * 1979-06-22 1981-01-16 Matsushita Electric Works Ltd Fireplace in floor
JPS5756494A (en) * 1980-09-22 1982-04-05 Microbial Chem Res Found New anthracyclin derivative
US4325947A (en) * 1981-05-12 1982-04-20 Farmitalia Carlo Erba S.P.A. 4-Demethoxy-4'-deoxydoxorubicin
IT1210476B (it) * 1981-05-28 1989-09-14 Erba Farmitalia Antracicline.
US4438105A (en) * 1982-04-19 1984-03-20 Farmaitalia Carlo Erba S.P.A 4'-Iododerivatives of anthracycline glycosides
FI75834C (fi) * 1982-05-24 1988-08-08 Erba Farmitalia Foerfarande foer framstaellning av antracyklinglykosidfoereningar.
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
CA1248944A (en) * 1982-09-28 1989-01-17 Gareth J. Thomas Anthracycline glycosides
JPS5982395A (ja) * 1982-11-02 1984-05-12 Microbial Chem Res Found アントラサイクリン化合物、その製造法およびその用途
GR79729B (enEXAMPLES) * 1982-12-20 1984-10-31 Univ Ohio State Res Found
JPS6092212A (ja) * 1983-10-26 1985-05-23 Kyowa Hakko Kogyo Co Ltd ドキソルビシン塩の製剤
US4537882A (en) * 1984-05-10 1985-08-27 Ohio State University 4-Demethoxy-3'-desamino-2'-halo-anthracycline and pharmaceutical composition containing same

Also Published As

Publication number Publication date
SG80290G (en) 1990-11-23
CN85107562B (zh) 1988-06-01
ZA858033B (en) 1986-06-25
FI86252C (fi) 1992-08-10
DK165620B (da) 1992-12-28
NO170616C (no) 1992-11-11
ES8605374A1 (es) 1986-03-16
NL191308C (nl) 1995-05-16
FI854035A0 (fi) 1985-10-16
PT81347A (en) 1985-11-01
NL191308B (nl) 1994-12-16
RU1836088C (ru) 1993-08-23
FR2571966A1 (fr) 1986-04-25
CN85107562A (zh) 1986-07-23
RU2101018C1 (ru) 1998-01-10
UA19169A (uk) 1997-12-25
IE852593L (en) 1986-04-22
IE56992B1 (en) 1992-02-26
AU4880585A (en) 1986-05-01
NO170616B (no) 1992-08-03
CH667594A5 (de) 1988-10-31
AU572003B2 (en) 1988-04-28
SE8504945D0 (sv) 1985-10-21
SE8504945L (sv) 1986-04-23
NL8502869A (nl) 1986-05-16
IL76732A (en) 1989-07-31
DE3536896C2 (de) 1996-11-14
KR860003014A (ko) 1986-05-19
FI853913A0 (fi) 1985-10-08
GB8426672D0 (en) 1984-11-28
MY103956A (en) 1993-10-30
YU164485A (en) 1987-10-31
HK94390A (en) 1990-11-23
AT401345B (de) 1996-08-26
FI853913A7 (fi) 1986-04-23
YU46160B (sh) 1993-05-28
GB8525709D0 (en) 1985-11-20
IL76732A0 (en) 1986-02-28
DE3536896A1 (de) 1986-04-24
BE903484A (fr) 1986-04-21
JPS61246129A (ja) 1986-11-01
NO854194L (no) 1986-04-23
US4675311A (en) 1987-06-23
SE467520B (sv) 1992-08-03
CA1248453A (en) 1989-01-10
ES547578A0 (es) 1986-03-16
US5091373A (en) 1992-02-25
PH23982A (en) 1990-02-09
KR920005813B1 (ko) 1992-07-20
DK165620C (da) 1993-06-01
CS756585A2 (en) 1989-11-14
BG60934B2 (bg) 1996-06-28
ATA303285A (de) 1996-01-15
HUT40759A (en) 1987-02-27
GB2165751A (en) 1986-04-23
CS270421B2 (en) 1990-06-13
FI86252B (fi) 1992-04-30
IT8522507A0 (it) 1985-10-16
US4840938A (en) 1989-06-20
UA34419C2 (uk) 2001-03-15
DK481585D0 (da) 1985-10-21
PT81347B (pt) 1987-11-11
DK481585A (da) 1986-04-23
FI854035L (fi) 1986-04-23
IT1186779B (it) 1987-12-16
NZ213885A (en) 1988-05-30
GR852549B (enEXAMPLES) 1986-02-24
US5091372A (en) 1992-02-25
JPH0611700B2 (ja) 1994-02-16
FR2571966B1 (fr) 1988-04-15
GB2165751B (en) 1988-08-17

Similar Documents

Publication Publication Date Title
HU197988B (en) Process for producing lyophilized pharmaceutical product containing anthracycline - glycoside - derivative
RU2118171C1 (ru) Фармацевтические композиции, содержащие антрациклиновые гликозиды, связанные с полимерным производным
EA002776B1 (ru) Фармацевтические композиции, содержащие циклодекстрины и таксоиды
WO2009118754A2 (en) A process for preparing a stable lyophilized composition
KR920001773B1 (ko) 안트라사이클린 글리코사이드 주사용 용액의 제조방법
KR101478779B1 (ko) 재수화시간이 향상된 택산 유도체 함유 동결건조 조성물 및이의 제조방법
EP1674105A1 (de) Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
WO2007124668A1 (fr) Composition pharmaceutique comportant un concentré élevé de polydatine
RU2315623C2 (ru) Жидкий препарат, содержащий производное кампототецина, и фармацевтическая композиция, получаемая путем лиофилизации препарата
JP2621255B2 (ja) アントラサイクリングリコシド溶液およびその製造方法
JP7423028B2 (ja) ボルテゾミブを含有する凍結乾燥医薬組成物
JPH0776515A (ja) 溶解性が改善された製剤の製造法
NO890198L (no) Stabilisert toerrpreparat av cytostatisk virksomt antracyclin-antibiotikum og fremgangsmaate for fremstilling av dette
HK1142820B (en) Injection, injection solution and injection kit preparation

Legal Events

Date Code Title Description
HU90 Patent valid on 900628
HPC4 Succession in title of patentee

Owner name: PHARMACIA ITALIA S.P.A., IT